عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Ma’aden, Royal Commission for Jubail and Yanbu Establish Mangrove Park to Preserve Coastal Ecosystems

The agreement was signed by Ma’aden CEO Robert Wilt and Royal Commission for Jubail and Yanbu CEO Mahmood Al Theeb
The agreement was signed by Ma’aden CEO Robert Wilt and Royal Commission for Jubail and Yanbu CEO Mahmood Al Theeb
TT
TT

Ma’aden, Royal Commission for Jubail and Yanbu Establish Mangrove Park to Preserve Coastal Ecosystems

The agreement was signed by Ma’aden CEO Robert Wilt and Royal Commission for Jubail and Yanbu CEO Mahmood Al Theeb
The agreement was signed by Ma’aden CEO Robert Wilt and Royal Commission for Jubail and Yanbu CEO Mahmood Al Theeb

Saudi Arabian Mining Company (Ma’aden) has signed a memorandum of understanding with the Royal Commission for Jubail and Yanbu to establish a mangrove park in the Kingdom, supporting carbon sequestration and biodiversity preservation.

The agreement was signed by Ma’aden CEO Robert Wilt and Royal Commission for Jubail and Yanbu CEO Mahmood Al Theeb, in the presence of Minister of Environment, Water and Agriculture Abdulrahman Al-Fadley, Minister of Industry and Mineral Resources Bandar Alkhorayef, and Deputy Minister for Mining Affairs Khalid Al-Mudaifer at the Saudi Green Initiative (SGI) which took place during the COP28 climate summit in Dubai.

Under the agreement, Ma’aden and the Royal Commission for Jubail and Yanbu will develop a mangrove park and support planting initiatives on Gurmah Island in Jubail, which houses a rich natural mangrove habitat.

The two parties will also cooperate on research initiatives relating to mangrove planting and ecosystem health and will develop local community programs that support ecosystem restoration and improve environmental awareness.

"This partnership is focused on preserving the Kingdom’s unique natural environment. Mangroves provide one of the most effective natural carbon-capture ecosystems and our ability strategy provides a roadmap towards restoring and enhancing the biodiversity of our coastline, in line with Ma’aden’s vision for sustainable growth in Saudi Arabia," Wilt said.

According to Al Theeb, the “partnership with Ma’aden will continue to preserve and expand mangrove ecosystems in Jubail."

“Together we will develop impactful initiatives that benefit the local community and contribute to the Kingdom’s sustainability objectives,” he said.

Ma’aden also launched a dedicated mangrove plantation strategy during SGI that aims to protect existing forests, restore degraded areas and contribute to carbon reduction and biodiversity enhancement. The company has committed to planting 10 million terrestrial trees and 10 million mangroves by 2040, in line with its ambitions as an environmental, social, and governance (ESG) leader to be carbon neutral by 2050.

The strategy supports the Saudi Green Initiative’s target to plant 100 million mangroves in Saudi Arabia by 2030, which will offset around 96 million tons of carbon emissions and help to stabilize the Kingdom’s coastline ecosystems.

Most Viewed

 
 
Varieties

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”